Drug Profile
Terlipressin - BioVie
Alternative Names: BIV-201; Continuous infusion terlipressin - BioVie; Terlipressin acetate continuous infusion - BioVieLatest Information Update: 15 Nov 2023
Price :
$50
*
At a glance
- Originator BioVie
- Class Antidiuretics; Antihaemorrhagics; Vasoconstrictors; Vasopressins
- Mechanism of Action Vasopressin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Ascites
- Preclinical Hepatorenal syndrome
Most Recent Events
- 13 Nov 2023 Updated adverse events data from a phase IIb trial in Ascites presented at the American Association for the Study of Liver Diseases (AASLD-2023)
- 13 Nov 2023 BioVie plans a pivotal phase III trial for Ascites (IV, Infusion), in Q2 2024
- 10 Nov 2023 Adverse events data from a phase IIb trial in Ascites presented at 74th Annual Meeting of the American Association for the Study of Liver Diseases ( AASLD-2023)